These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 22874836

  • 1. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2012 Aug 10; 61(31):586-9. PubMed ID: 22874836
    [Abstract] [Full Text] [Related]

  • 2. [HIV preexposure prophylaxis].
    Olczak A, Grabczewska E.
    Przegl Epidemiol; 2012 Aug 10; 66(1):79-82. PubMed ID: 22708303
    [Abstract] [Full Text] [Related]

  • 3. Considerations regarding antiretroviral chemoprophylaxis in MSM.
    Poynten IM, Zablotska I, Grulich AE.
    Curr Opin HIV AIDS; 2012 Nov 10; 7(6):549-56. PubMed ID: 22918448
    [Abstract] [Full Text] [Related]

  • 4. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
    Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Were E, Heffron R, Matthews LT, Morrison S, Ngure K, Baeten JM, Partners PrEP Study Team.
    JAMA; 2012 Nov 10; 312(4):362-71. PubMed ID: 25038355
    [Abstract] [Full Text] [Related]

  • 5. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM, Mayer KH.
    AIDS Patient Care STDS; 2011 Feb 10; 25(2):63-71. PubMed ID: 21284497
    [Abstract] [Full Text] [Related]

  • 6. Pre-exposure chemoprophylaxis of HIV infection: quo vadis?
    Clercq ED.
    Biochem Pharmacol; 2012 Mar 01; 83(5):567-73. PubMed ID: 22067069
    [Abstract] [Full Text] [Related]

  • 7. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM, Partners PrEP Study Team.
    Ann Intern Med; 2014 Jul 01; 161(1):11-9. PubMed ID: 24979446
    [Abstract] [Full Text] [Related]

  • 8. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2011 Jan 28; 60(3):65-8. PubMed ID: 21270743
    [Abstract] [Full Text] [Related]

  • 9. Systemic preexposure prophylaxis for human immunodeficiency virus infection.
    Romanelli F, Murphy B.
    Pharmacotherapy; 2010 Oct 28; 30(10):1021-30. PubMed ID: 20874040
    [Abstract] [Full Text] [Related]

  • 10. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C, Partners PrEP Study Team.
    N Engl J Med; 2012 Aug 02; 367(5):399-410. PubMed ID: 22784037
    [Abstract] [Full Text] [Related]

  • 11. Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2013 Jun 14; 62(23):463-5. PubMed ID: 23760186
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
    Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM, Partners PrEP Study Team.
    AIDS; 2013 Aug 24; 27(13):2155-60. PubMed ID: 24384592
    [Abstract] [Full Text] [Related]

  • 13. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
    Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J, Koenig LJ, Valleroy LA.
    MMWR Morb Mortal Wkly Rep; 2015 Nov 27; 64(46):1291-5. PubMed ID: 26606148
    [Abstract] [Full Text] [Related]

  • 14. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E, Cohan D.
    AIDS; 2013 Jan 02; 27(1):F1-5. PubMed ID: 22914582
    [Abstract] [Full Text] [Related]

  • 15. Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France.
    Lorente N, Fugon L, Carrieri MP, Andreo C, Le Gall JM, Cook E, Aboulker JP, Capitant C, Molina JM, Spire B.
    AIDS Care; 2012 Jan 02; 24(4):468-77. PubMed ID: 22085083
    [Abstract] [Full Text] [Related]

  • 16. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D, Mayer KH.
    Ann Intern Med; 2012 Oct 02; 157(7):490-7. PubMed ID: 22821365
    [Abstract] [Full Text] [Related]

  • 17. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.
    AIDS; 2009 Apr 27; 23(7):825-33. PubMed ID: 19307941
    [Abstract] [Full Text] [Related]

  • 18. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers.
    Blum MR, Chittick GE, Begley JA, Zong J.
    J Clin Pharmacol; 2007 Jun 27; 47(6):751-9. PubMed ID: 17519400
    [Abstract] [Full Text] [Related]

  • 19. Prevention. Using PrEP cost-effective in high-risk MSM groups.
    AIDS Policy Law; 2012 Jun 27; 27(7):1. PubMed ID: 22803211
    [No Abstract] [Full Text] [Related]

  • 20. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis.
    Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, McMahan V, Kallas EG, Montoya-Herrera O, Pilotto J, Grant RM.
    PLoS One; 2013 Jun 27; 8(12):e81997. PubMed ID: 24367497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.